These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 19793708)

  • 1. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
    Ault P; Jones K
    Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
    Shander A; Cappellini MD; Goodnough LT
    Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
    Kwiatkowski JL; Cohen AR
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
    Ho PJ; Tay L; Lindeman R; Catley L; Bowden DK
    Intern Med J; 2011 Jul; 41(7):516-24. PubMed ID: 21615659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A; Sazama K
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in improving the management of sickle cell disease.
    Inati A
    Blood Rev; 2009 Dec; 23 Suppl 1():S9-13. PubMed ID: 20116638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.